Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

What Was Tested

The paper reports a study of Insulin Aspart and Insulin Detemir, published as a randomized controlled trial.

Insulin degludec (IDeg) once-daily was compared with insulin detemir (IDet) once- or twice-daily, with prandial insulin aspart in a treat-to-target, randomized controlled trial in children 1-17 yr with type 1 diabetes, for 26 wk (n = 350), followed by a 26-wk extension (n = 280).

Aspart was titrated according to a sliding scale or in accordance with an insulin:carbohydrate ratio and a plasma glucose correction factor.

Who Took Part

The study group was 85 subjects.

The age groups tagged for this paper are infants, young children, children and teenagers.

Participants were randomized to receive either IDeg once daily at the same time each day or IDet given once or twice daily according to local labeling.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

(IDeg: 43), 138 6-11 yr (IDeg: 70) and 127 12-17 yr (IDeg: 61) were included.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 1, Diabetic Ketoacidosis, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents, Insulin Aspart and Insulin Detemir.

The authors tagged it with the keywords adolescents, children, insulin degludec and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized study of Insulin Aspart and Insulin Detemir in 85 subjects.

The publication is from 2015 (Pediatric diabetes), a journal based in China.

More context: the Insulin Aspart compound page and the Insulin Detemir compound page.